olodanrigan [Ligand Id: 8374] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL34124 (Ema401, EMA-401, EMA401, Olodanrigan, PD-126055) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| AT2 receptor/Angiotensin II type 2 (AT-2) receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4607] [GtoPdb: 35] [UniProtKB: P50052] | ||||||||
| ChEMBL | Binding affinity to type-2 angiotensin-2 receptor (unknown origin) | B | 7.4 | pKi | 39.5 | nM | Ki | Bioorg Med Chem Lett (2016) 26: 1355-1359 [PMID:26810314] |
| ChEMBL | Inhibition of human AT2 receptor | B | 5 | pIC50 | >10000 | nM | IC50 | J Med Chem (2020) 63: 1978-1995 [PMID:32030982] |
| ChEMBL | Inhibitory activity was evaluated against Angiotensin II receptor, type 2 | B | 9.22 | pIC50 | 0.6 | nM | IC50 | J Med Chem (1996) 39: 625-656 [PMID:8576904] |
| ChEMBL | In vitro binding affinity of compound was measured against angiotensin II (AT2) receptor | B | 9.24 | pIC50 | 0.58 | nM | IC50 | Bioorg Med Chem Lett (1994) 4: 1479-1484 |
| GtoPdb | - | - | 9.3 | pIC50 | - | - | IC50 |
Lancet (2014) 383: 1637-47 [PMID:24507377]; Pain Med (2013) 14: 692-705 [PMID:23489258]; Lancet (2014) 383: 1613-4 [PMID:24507378] |
| AT2 receptor in Rat [GtoPdb: 35] [UniProtKB: P35351] | ||||||||
| GtoPdb | - | - | 7.53 | pIC50 | 29.5 | nM | IC50 | Pain Med (2013) 14: 692-705 [PMID:23489258] |
| AT1 receptor/Type-1 angiotensin II receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL227] [GtoPdb: 34] [UniProtKB: P30556] | ||||||||
| ChEMBL | Inhibition of human AT1 receptor | B | 7.41 | pIC50 | 39 | nM | IC50 | J Med Chem (2020) 63: 1978-1995 [PMID:32030982] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
